Contraceptive devices: Intravaginal and intrauterine delivery systems

Expert Review of Medical Devices

Volumn 5, Issue 5, 2008, Pages 639-654

  Benagiano, Giuseppe ^a   Gabelnick, Henry ^b   Farris, Manuela ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Contraceptive device; Intrauterine device; Intrauterine system; Long acting fertility regulating agent; Vaginal ring

Indexed keywords

COPPER INTRAUTERINE DEVICE; DESOGESTREL; DIMETICONE; ELCOMETRINE; ESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; FIBROPLANT; FLEXIGARD; GESTAGEN; GYNEFIX; LEVONORGESTREL; MULTILOAD COPPER INTRAUTERINE DEVICE; NONSTEROID ANTIINFLAMMATORY AGENT; NUVA RING; ORAL CONTRACEPTIVE AGENT; PROGERING; PROGESTERONE; SPERMICIDAL AGENT; UNCLASSIFIED DRUG; ESTROGEN;

APPLICATION SITE INFECTION; APPLICATION SITE PAIN; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTRACEPTION; CONTROLLED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; ECTOPIC PREGNANCY; ENDOPROSTHESIS LOOSENING; FEMALE CONTRACEPTIVE DEVICE; HORMONE ACTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENORRHAGIA; MENSTRUATION DISORDER; MONOTHERAPY; NAUSEA AND VOMITING; PELVIC INFLAMMATORY DISEASE; PREGNANCY RATE; REVIEW; SEXUAL DYSFUNCTION; SEXUAL INTERCOURSE; SIDE EFFECT; TREATMENT FAILURE; UTERUS PERFORATION; VAGINA BLEEDING; VAGINA DISEASE; VAGINA RING; WITHDRAWAL BLEEDING; DRUG DELIVERY SYSTEM; FEMALE; INTRAVAGINAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVAGINAL; DRUG DELIVERY SYSTEMS; ESTROGENS; FEMALE; HUMANS; INTRAUTERINE DEVICES; PROGESTINS;

EID: 55249127046     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.5.5.639     Document Type: Review

References (134)

1. Benagiano G, Gabelnick H, Farris M. Contraceptive devices: subcutaneous delivery-systems. Expert. Rev. Med. Devices 5(5), 623-637 (2008).
2. Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J. Control. Release 103, 301-313 (2005).
3. Coutinho EM, O'Dwyer E, Barbosa IC et al. Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route. Contraception 51, 355-358 (1995).
4. Diaz S. Contraceptive vaginal rings. Internat. Plann. Parenthood Fed. Med. Bull. 33, 3-4 (1999).
5. Lahteenmaki P, Jukarainen H. Novel delivery systems in contraception. Br. Med. Bull. 56, 739-748 (2000).
6. Harwood B, Mishell DR Jr. Contraceptive vaginal rings. Semin. Reprod. Med. 19, 381-390 (2001).
7. Johansson ED, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am. J. Obstet. Gynecol. 190(Suppl. 4), S54-S59 (2004).
8. Sitruk-Ware R. Delivery options for contraceptives. Drug Discov. Today 10, 977-985(2005).
9. Sitruk-Ware R. Contraception: an international perspective. Contraception 73, 215-222 (2006).
10. Weisberg E, Fraser IS, Mishell DR Jr, Lacarra M, Darney P, Jackanicz TM. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception 59, 305-310 (1999).
11. Roumen FJ, Apter D, Mulders TM, Dieben TQ. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum. Reprod. 16, 469-475 (2001).
12. Dieben TOM, Roumen FJME, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet. Gynecol. 100, 585-593 (2002).
13. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin. Pharmacokinet. 39, 233-242 (2000).
14. van den Heuvel MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72, 168-174 (2005).
15. Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ ethinyl estradiol. Am. J. Obstet. Gynecol. 186, 389-395 (2002).
16. Bruni V, Pontello V, Luisi S, Petraglia F. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing®. Eur. J. Obstet. Gynecol. Reprod. Biol. 139(1), 65-71 (2008).
17. Roumen FJME. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 75, 420-429 (2007).
18. Sivin I, Mishell Jr D, Alvarez F et al. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception 71, 122-129 (2005).
19. Fraser IS, Weisberg E, Brache V et al. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen. Contraception 72, 40-45 (2005).
20. Mishell DR Jr. Vaginal contraceptive rings. Ann. Med. 25, 191-197 (1993).
21. Koetsawang S, Ji G, Krishna U et al. World Health Organization. Task force on long-acting systemic agents for fertility regulation. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. Contraception 41, 105-124 (1990).
22. Koetsawang S, Ji G, Krishna U et al. World Health Organization. Task force on long-acting systemic agents for fertility regulation. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. Contraception 41, 125-141 (1990).
23. Koetsawang S, Ji G, Krishna U et al. World Health Organization. Task force on long-acting systemic agents for fertility regulation. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. III. The relationship between pregnancy rate and body weight. Contraception 41, 143-150 (1990).
24. Koetsawang S, Ji G, Krishna U et al. World Health Organization. Task force on long-acting systemic agents for fertility regulation; Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. IV. Bleeding patterns. Contraception 41, 151-167 (1990).
25. Special Programme of Research, Development and Research Training in Human Reproduction. Annual Technical Report 1995. World Health Organization, Geneva, Switzerland 36-37 (1996).
26. Bounds W, Szarewski A, Lowe D, Guillebaud J. Preliminary report of unexpected local reactions to a progestogen- releasing contraceptive vaginal ring. Eur. J. Obstet. Gynecol. Reprod. Biol. 48, 123-125 (1993).
27. Special Programme of Research, Development and Research Training in Human Reproduction. Annual Technical Report 1997. World Health Organization, Geneva, Switzerland 75-76 (1998).
28. Special Programme of Research, Development and Research Training in Human Reproduction. Annual Technical Report 1999. World Health Organization, Geneva, Switzerland 127-128 (2000).
29. Massai, R. Miranda P, Valdés P et al. Pre-registration study on the safety and contraceptive efficacy of a progesterone- releasing vaginal ring in Chilean nursing women. Contraception 60, 9-14 (1999).
30. Massai R, Diaz S, Jackanicz T, Croxatto HB. Vaginal rings for contraception in lactating women. Steroids 65, 703-707 (2000).
31. Brache V, Mishell DR, Lahteenmaki P et al. Ovarian function during use of vaginal rings delivering three different doses of Nestorone. Contraception 63, 257-261 (2001).
32. Sitruk-Ware R, Small M, Kumar N, Tsong Y-Y, Sundaram K, Jackanicz T. Nestorone®: clinical applications for contraception and HRT Steroids 68, 907-913 (2003).
33. Massai MR, Diaz S, Quinteros E et al. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception 64, 369-376 (2001).
34. Sivin I, Croxatto H, Bahamondes L et al. Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women. Contraception 69, 137-144 (2004).
35. Sivin I. Croxatto HB, Saxena BB et al. Efficacy of non-hormonal vaginal contraceptives from a hydrogel delivery system. Contraception 70, 213-219 (2004).
36. Southam AL. Historical review of intrauterine devices. In: Intrauterine Contraception. Segal SJ, Southam AL, Shaffer KD, (Eds). Excerpta Med. Int. Congress Series 86, 3-9 (1965).
37. Richter R. Ein Mittel zur Verhütung der Konzeption. Dtsch. Med. Wochenschr. 35, 1525 (1909).
38. Graefenberg E. An Intrauterine Contraceptive Method. Sanger M, Stone HM (Eds). Williams and Wilkins Co., Baltimore, MD, USA, 336 (1931).
39. Ota T. A study on the birth control with an intrauterine istrument. J. Jpn. Obstet. Gynecol. Soc. 17, 210-214 (1934).
40. Guttmacher AF. Intrauterine contraceptive devices. J. Reprod. Fertil. 10, 115-128 (1965).
41. Lippes J. A study of intrauterine contraception: development of a plastic loop. In: Intrauterine Contraceptive Devices. Tietze C, Lewit S (Eds). Excerpta Medica, Amsterdam, The Netherlands, 166 (1962).
42. Rowe PJ. Medicated intrauterine devices: a review. In: WHO Symposium on Advances in Fertility Regulation. Copenhagen, Denmark, 381-406 (1977).
43. Zipper J, Medel M, Prager R. Suppression of fertility by intrauterine copper and zinc in rabbits. Am. J. Obstet. Gynecol. 105, 529-534 (1969).
44. D'Arcangues C. World-wide use of intrauterine devices for contraception. Contraception 75(Suppl. 6), S2-S7 (2007).
45. World Health Organisation, Special Programme of Research, Development and Research Training in Human Reproduction and Task Force on the Safety and Efficacy of Fertility Regulating Methods. The TCu380A, TCu220C, multiload 250 and nova T IUDs at 3, 5 and 7 years of use - results from three randomized multicentre trials Contraception 42, 141-158 (1990).
46. Sivin I, Greenslade F, Schmidt F, Waldman SN. The Copper T 380 Intrauterine Device: A Summary of Scientific Data. The Population Council, NY, USA (1992).
47. WHO. Special Programme of Research, Development and Research Training in Human Reproduction. In: Biennial Report 1990-1991 - Reproductive health: a key to a brighter future. World Health Organization, Geneva, Switzerland, 80-93 (1992).
48. Rowe PJ, Boccard S, Farley TMM, Peregoudov S; World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction. Long-term reversible contraception: twelve years of experience with the TCu380A and TCu220C. Contraception 56, 341-352 (1997).
49. UNDP/UNFPA/WHO/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction: IUD Research Group A randomized multicentre trial of the Multiload 375 and TCu380A in parous women: three-years results. Contraception 49, 543-549 (1994).
50. Department of Reproductive Health and Research. Annual Technical Report 2002. World Health Organization, Geneva, Switzerland, 54-60 (2003).
51. WHO Special Programme of Research in Human Reproduction. Highlights of 2005. World Health Organization, Geneva, Switzerland (2006).
52. O'Brien PA, Kulier R, Helmerhorst FM et al. Copper-containing, framed intrauterine devices for contraception: a systematic review of randomized controlled trials. Contraception 77, 318-327 (2008).
53. Grimes D, Schulz K, Stanwood N. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst. Rev. 4, CD001777 (2004).
54. Lara-Ricalde R, Menocal Tobias G, Ramos Pérez C, Velázquez Ramírez N. Random comparative study between intrauterine device Multiload Cu375 and TCu 380a inserted in the postpartum period [In Spanish]. Ginecol. Obstet. Mex. 74, 306-311 (2006).
55. Eroglu K, Akkuzu G, Vural G et al. Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception 74, 376-381 (2006).
56. Grimes DA, Hubacher D, Lopez LM, Schulz KF. Non-steroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use. Cochrane Database Syst. Rev. CD006034 (2006).
57. Hubacher D, Reyes V, Lillo S et al. Preventing copper intrauterine device removals due to side-effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen. Hum. Reprod. 21, 1467-1472 (2006).
58. Sivin I. Utility and drawbacks of continuous use of a copper IUD for twenty years. Contraception 75(Suppl. 6), S70-S75 (2007).
59. French R, Van Vliet H, Cowan F et al. Hormonally impreganted intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst. Rev. CD001776 (2004).
60. Andersson K, Ryde-Blomqvist E, Lindell K et al. Perforations with intrauterine devices. Report from a Swedish survey. Contraception 57, 251-255 (1998).
61. WHO. Special Programme of Research, Development and Research Training in Human Reproduction. In: Annual Technical Report 1998. World Health Organization, Geneva, Switzerland, 89-150 (1999).
62. Buchan H, Villard-Mackintosh L, Vessey M, Yeates D, McPherson K. Epidemiology of pelvic inflammatory disease in parous women with special reference to intrauterine device use. Br. J. Obstet. Gynaecol. 97, 780-788 (1990).
63. Population Council. Copper T, model Tcu200. The Population Council, NY, USA (1975).
64. Garmo HG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility - follow-up after participation in a randomized clinical trial. Contraception 75, 88-92 (2007).
65. World Health Organization. Mechanism of action, safety and efficacy of intrauterine devices. World Health Organ. Tech. Rep. Ser. 753, 25 (1987).
66. Salman G, Irvine LM. Ectopic pregnancy, the need for standardisation of rate. J. Obstet. Gynaecol. 28, 32-35 (2008).
67. Coste J, Bouver J, Germain E et al. Recent declining trend in ectopic pregnancy in France: evidence of two clinicoepidemiologic entities. Fertil. Steril. 74, 881-886 (2000).
68. Coste J, Bouyer J, Ughetto S et al. Ectopic pregnancy is again on the increase. Recent trends in the incidence of ectopic pregnancies in France (1992-2002). Hum. Reprod. 19, 2014-2018 (2004).
69. Sivin I. Ectopic pregnancy risk and the IUD. In: State of the Art of the IUD. Van der Pass HFM, Dieben TOM (Eds). Kluwer Acad. Publ., London, UK, 150-154 (1989).
70. Xiong X, Buekens P, Wollast E. IUD use and the risk of ectopic pregnancy: a meta-analysis of case-control studies. Contraception 52, 23-34 (1995).
71. Faculty of Family Planning and Reproductive Health Care. Clinical effectiveness unit guidance: the copper intrauterine device as long-term contraception. J. Fam. Plann. Reprod. Health Care 30(1), 29-42 (2004).
72. Sivin I. IUDs are contraceptives, not abortifacients: a comment on research and beliefs. Stud. Fam. Plann. 20, 355-359 (1989).
73. Croxatto HB, Ortiz ME, Valdez E. IUD mechanism of action. In: Proceedings of the 4th International Conference on IUDs. Bardin CW, Mishell RD (Eds). Butterworth-Heinemann, Boston, USA, 44-62 (1994).
74. Ortiz ME, Croxatto MB, Bardin CW. Mechanism of action of intrauterine devices. Obstet. Gynecol. Surv. 51, S42-S51 (1996).
75. Ortiz ME, Croxatto HB. Copper-T intrauterine.device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 75(Suppl. 6), S16-S30 (2007).
76. Roblero L, Guadarrama A, Lopez T, Zegers-Hochschild F. Effect of copper ion on the motility, viability, acrosome reaction and fertilizing capacity of human spermatozoa in vitro. Reprod. Fertil. Dev. 8, 871-874 (1996).
77. Parr EL, Shirley RL. Embryotoxicity of leucocyte extracts and its relationship to intrauterine contraception in humans. Fertil. Steril. 27, 1067-1077 (1976).
78. Wilcox AJ, Weimberg CR, Armstrong EG, Canfield RE. Urinary human chorionic gonadotropin among intrauterine device users: detection with a highly specific and sensitive assay. Fertil. Steril. 47, 265-269 (1987).
79. Benagiano G, Mori M. The evolution of the thinking of the Catholic Church on the beginning of human life. Reprod. Biomed. Online 14(Suppl. 1), 162-168 (2006).
80. Doyle LL, Clewe TH. Preliminary studies on the effect of hormone releasing intrauterine devices. Am. J. Obstet. Gynecol. 101, 564-570 (1968).
81. Stryker JC, Doyle LL, Clewe TH, Lippes J. Silastic. Lippes Loop with Crystalline Provera. Excerpta Medica. Int. Congress Series, Amsterdam, The Netherlands, 246 (1971).
82. Scommegna A, Pandya GN, Christ M, Lee AW, Cohen MR. Intrauterine administration of progesterone by a slow release device. Fertil. Steril. 21, 210-214 (1970).
83. Pandya GN, Scommegna A. Intrauterine progesterone-releasing devices: a clinical trial. Excerpta Med. Sobrero AJ, Harvey RM (Eds). Amsterdam, The Netherlands 103 (1972).
84. Pharris BB, Ericsson R, Bashaw J, Hoff S, Place V, Zaffaron i A. Progestasert®: a uterine therapeutic system for contraception. Fertil. Steril. 25, 915-962 (1974).
85. Carenza L, Ermini M, Pala A, Benagiano G. Efferto dei dispositivi intrauterine liberand progesterone sull'asse ipotalamo-ipofiso-ovarico nella donna. Patol. Clin. Ostet. Ginecol. 4, 109-115 (1976).
86. Wan LS, Hsu YC, Ganguly M, Bigelow B. Effects of the Progestasert on the menstrual pattern, ovarian steroid and endometrium. Contraception 16, 417-434 (1977).
87. Carenza L, Ermini M, Pala A, Benagiano G. Effect of the uterine progesterone system on the hormonal profile in the human. In: Proceedings of the Fourth European Sterility Congress. Excerpta med. Amsterdam, The Netherlands, 329-332 (1979).
88. Hagenfeldt K, Landgren B-M. Contraception by intrauterine release of progesterone - effects on endometrial trace elements enzymes and steroids. J. Steroid Biochem. 6, 895-898 (1975).
89. Hagenfeldt K, Landgren B-M, Edström K, Johannisson E. Biochemical and morphological changes in the human endometrium induced by the progestasert device. Contraception 16, 183-197 (1977).
90. Ermini M, Carpino V, Petrozza V, Benagiano G. Distribution and effect on the endometrium of progesterone released from a progestasert device. Hum. Reprod. 4, 221-228 (1989).
91. Shaw ST, Macaulay LK, Aznar R, González-Angulo A, Roy S. Effect of progesterone-releasing intrauterine contraceptive device on endometrial blood vessels: a morphometric study. Am. J. Obstet. Gynecol. 141, 829-839 (1981).
92. Snowden R. The Progestasert and ectopic pregnancy. Br. Med. J. 2, 1600-1601(1977).
93. Jones RC. The effects of an intrauterine device containing norgestrel in the rat. Fertil. Steril. 25, 767-771 (1974).
94. Nilsson CG, Johansson EDB, Jackanicz TM, Luukkainen T. Biodegradable polylactate as a steroid-releasing polymer: Intrauterine administration of d-norgestrel. Am. J. Obstet. Gynecol. 122, 90-95 (1975).
95. Nilsson C-G, Johansson EDB, Luukkainen TA. D-norgestrel-releasing IUD. Contraception 13, 503-514 (1976).
96. Nilsson CG, Lähteenmäki PL, Luukkainen T, Robertson DN. Sustained intrauterine release of levonorgestrel over five years. Fertil. Steril. 45, 805-807 (1986).
97. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin. Reprod. Med. 19, 355-363 (2001).
98. Luukkainen T, Pakarinen P. Contraceptive efficacy and safety of the levonorgestrel-releasing intrauterine system (Mirenal®). Gynaecol. Forum 11, 4-6 (2006).
99. Luukkainen T. Levonorgestrel-releasing intrauterine device. Ann. NY Acad. Sci. 626, 43-49 (1991).
100. French RS, Cowan FM, Mansour D et al. Levonorgestrel-releasing (20μg/day) intrauterine system (Mirena®) compared with other method of reversible contraception. BJOG 107, 1218-1225 (2000).
101. Andersson K, Odlind V, Rybo G. Levonorgestrel releasing and copper releasing (Nova T) IUDs during five years of use: a randomized. trial. Contraception 49, 56-72 (1994).
102. Faculty of Family Planning and Reproductive Health Care. CEU Guidance: the levonorgestel releasing system (LNG-IUS) in contraception and reproductive health. J. Fam. Plann. Reprod. Health Care 30, 99-109 (2004).
103. Faundes A, Alvarez F, Díaz J. A Latin American experience with levonorgestrel IUD. Ann. Med. 25, 149-153 (1993).
104. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20μg/d and Copper Tcu 380Ag intrauterine contraceptive devices: a multicentre study. Fertil. Steril. 61, 70-77 (1994).
105. Harrison-Woolrych M, Zhou L, Coulter D. Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu375 during post marketing monitoring in New Zealand. NZ Med. J. 8, 116-117 (2003).
106. Pakarinen P Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel and copper releasing intrauterine systems immediately after abortion with 5 years follow-up. Contraception 68, 31-34 (2003).
107. Standford JB, Mikolajczyk RT. Mechanism of action of intrauterine devices: update and estimation of post-fertilization effects. Am. J. Obstet. Gynecol. 187, 1699-1708 (2002).
108. Luukkainen T, Lahteenmaki PLA, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann. Med. 22, 85-90 (1990).
109. Barbosa I, Bakos O, Olsson SE et al. Ovarian function during use of a levonorgestrel-releasing IUD: Contraception 42, 51-66 (1990).
110. Nilsson C-G, Lahreemaki PLA, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil. Steril. 41, 52-55 (1984).
111. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am. J. Obstet. Gynecol. 181, 1263-1269 (1999).
112. Jonsson B, Landgren B-M, Eneroth P. Effects of various IUDs on the composition of cervical mucus. Contraception 43, 447-458 (1991).
113. Munuce MJ, Nascimento JA, Rosario G et al. Doses of levonorgestrel comparable to that delivered by the levonorgestrel-releasing intrauterine system can modify the in vitro expression of zona binding sites of human spermatozoa. Contraception 73, 97-101 (2006).
114. Backman T, Rauramo I, Huhtala S, Skoskenvuo M. Pregnancy during the use of levonorgestrel releasing system. Am. J. Obstet. Gynecol. 190, 50-54 (2004).
115. Lukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 65, 699-702 (2000).
116. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkilä A, Walker JJ, Cameron IT. Randomized comparative trial of levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br. J. Obstet. Gynaecol. 105, 592-598(1998).
117. Stewart A, Cummins C, Gold L et al. Effectiveness of the levonorgestrel releasing intrauterine system in menorrhagia: a systematic review. Br. J. Obstet. Gynaecol. 108, 74-86 (2001).
118. Pakarinen P, Lukkainen T. Treatment of menorrhagia with an LNG-IUS. Contraception 75, S118-S122 (2007).
119. Andersson K, Bacar I, Rybo G. Return to fertility after removal of a levonorgestrel releasing intrauterine device and Nova T. Contraception 46, 575-584 (1992).
120. French RS, Cowan FM, Mansour D et al. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraception: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol. Assess. 4, 1-107 (2000).
121. Batar I. One-year clinical experience with FlexiGard. Contraception 46, 307-312 (1992).
122. Van Kets H, Wilderneersch D, van der Pas H et al. IUD expulsion solved with implant technology. Contraception 51, 87-92 (1995).
123. Wildemeersch D. Further information and recommendations to prevent perforation with the frameless GyneFix IUD. J. Fam. Plann. Reprod. Health Care 27, 241 (2001).
124. Brockmeyer A, Kishen M, Webb A. New GyneFix introducer. J. Fam. Plann. Reprod. Health Care 30, 65 (2004).
125. O'Brien PA, Marfleet C. Frameless versus classical-intrauterine device for contraception. Cochrane Database Syst. Rev. 1, CD003282 (2005).
126. Delbarge W, Bátár I, Bafort M et al. Return to fertility in nulliparous and parous womena after removal of the GynueFix intrauterine contraceptive system. Eur. J. Contracept. Reprod. Health Care 7, 24-30 (2002).
127. Cao X, Zhang W, Zhao X et al. Three-year efficacy and acceptability of the GyneFix 200 intrauterine system. Contraception 69, 207-211 (2004).
128. Wu S, Hu J, Wildemeersch D. Performance of the frameless GyneFix and the TCu380A IUDs in a 3-year multicenter, randomized, comparative trial in parous women. Contraception 61, 91-98 (2000).
129. Wildemeersch D, Batár I, Affandi B et al. The 'frameless' intrauterine system for long-term, reversible contraception: a review of 15 years of clinical experience. J. Obstet. Gynaecol. Res. 29, 164-173 (2003).
130. Wildemeersch D, Schacht E, Wildemeersch P, Janssens D, Thiery M. Development of a miniature, low-dose, frameless intrauterine levonorgestrel-releasing system for contraception and treatment: a review of initial clinical experience. Reprod. Biomed. Online 4, 71-82 (2002).
131. Wildemeersch D, Schacht E, Wildemeersch P. Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study. Contraception 66, 93-99 (2002).
132. Wildemeersch D, Janssens D, Vrijens M, Weyers S. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems. Presented at the Proceedings of the 8th Congress of the European Society of Contraception. Edinburgh, Scotland 23-26 (2004).
133. Wildemeersch D. New frameless and framed intrauterine devices and systems - an overview. Contraception 75(Suppl. 6), S82-S92(2007).
134. O'Brien PA, Marfleet C. Frameless versus classical intrauterine device for contraception. Cochrane Database Syst. Rev. CD001776 (2004).